Cargando…

Biomarkers of Histone Deacetylase Inhibitor Activity in a Phase 1 Combined-Modality Study with Radiotherapy

BACKGROUND: Following the demonstration that histone deacetylase inhibitors enhanced experimental radiation-induced clonogenic suppression, the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study, combining fractionated radiotherapy with daily vorinostat for pelvic carcinoma, was designed to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ree, Anne Hansen, Saelen, Marie Grøn, Kalanxhi, Erta, Østensen, Ingrid H. G., Schee, Kristina, Røe, Kathrine, Abrahamsen, Torveig Weum, Dueland, Svein, Flatmark, Kjersti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934935/ https://www.ncbi.nlm.nih.gov/pubmed/24587009 http://dx.doi.org/10.1371/journal.pone.0089750

Ejemplares similares

Tumor Phosphatidylinositol-3-Kinase Signaling and Development of Metastatic Disease in Locally Advanced Rectal Cancer
por: Ree, Anne Hansen, et al.
Publicado: (2012)

Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
por: Kalanxhi, Erta, et al.
Publicado: (2017)

Biomarkers of Treatment Toxicity in Combined-Modality Cancer Therapies with Radiation and Systemic Drugs: Study Design, Multiplex Methods, Molecular Networks
por: Ree, Anne Hansen, et al.
Publicado: (2014)

Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2016)

Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
por: Kalanxhi, Erta, et al.
Publicado: (2016)

Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
por: Schee, Kristina, et al.
Publicado: (2012)

Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
por: Meltzer, Sebastian, et al.
Publicado: (2019)

Corrigendum to “Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer” [Transl Oncol 12 (8) (2019) 1038–1044]
por: Meltzer, Sebastian, et al.
Publicado: (2019)

Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
por: Saelen, Marie Grøn, et al.
Publicado: (2012)

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
por: Kalanxhi, Erta, et al.
Publicado: (2018)

Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
por: Hektoen, Helga Helseth, et al.
Publicado: (2015)

Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
por: Bratland, Åse, et al.
Publicado: (2011)

Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
por: Fleten, Karianne Giller, et al.
Publicado: (2020)

Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
por: Saelen, Marie Grøn, et al.
Publicado: (2011)

Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
por: Bains, Simer J., et al.
Publicado: (2019)

Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
por: Flatmark, Kjersti, et al.
Publicado: (2006)

Anti-Angiogenic Treatment in Pseudomyxoma Peritonei—Still a Strong Preclinical Rationale
por: Andersson, Yvonne, et al.
Publicado: (2021)

High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
por: Abrahamsson, Hanna, et al.
Publicado: (2019)

Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer()()
por: Bousquet, Paula A., et al.
Publicado: (2018)

Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer
por: Kalanxhi, Erta, et al.
Publicado: (2020)

Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer
por: Røe, Kathrine, et al.
Publicado: (2013)

A comprehensive framework for analysis of microRNA sequencing data in metastatic colorectal cancer
por: Høye, Eirik, et al.
Publicado: (2022)

Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
por: Jonsson, Marte, et al.
Publicado: (2016)

The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2021)

Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning (1)H magnetic resonance spectroscopy
por: Seierstad, Therese, et al.
Publicado: (2008)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Confidence interval methods for antimicrobial resistance surveillance data
por: Kalanxhi, Erta, et al.
Publicado: (2021)

Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response
por: Lund-Andersen, Christin, et al.
Publicado: (2019)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Thorgersen, Ebbe Billmann, et al.
Publicado: (2021)

Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
por: Meltzer, Sebastian, et al.
Publicado: (2019)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Regulation of Osteoclast Differentiation and Skeletal Maintenance by Histone Deacetylases
por: Faulkner, Bora, et al.
Publicado: (2019)

Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy
por: Blattmann, Claudia, et al.
Publicado: (2015)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t9t1vcacvm381ufng9q2gclb8p